Edwards Lifesciences Completes Sale of Critical Care
2024年9月4日 - 5:30AM
ビジネスワイヤ(英語)
Company announces $1 billion share
repurchase
Edwards Lifesciences (NYSE: EW) has successfully completed the
sale of its Critical Care product group to BD (Becton, Dickinson
and Company) (NYSE: BDX) for $4.2 billion in an all-cash
transaction. The net proceeds from the sale will be used to fund
strategic initiatives including the previously announced
acquisitions and share repurchases.
“Critical Care has made significant contributions to our company
and has a long history of innovation. We are grateful to the team
for their commitment to improving patient outcomes globally,” said
Bernard Zovighian, Edwards’ CEO. “The sale of Critical Care
reflects our sharpened focus as a structural heart innovator.
Within our existing business, TAVR has significant opportunities to
grow and improve how AS patients are treated, TMTT’s contribution
to Edwards’ growth is just getting started, and we continue to
expand our surgical leadership. In addition, our focus will support
patients in need of therapies to treat aortic regurgitation and
non-valvular structural heart disease through implantable
technologies.”
Edwards also announced today that its Board of Directors
authorized an additional $1.5 billion for share repurchase. The
Company recently entered into a $500 million Accelerated Share
Repurchase agreement, and previously in August repurchased $500
million of common stock through a 10b5-1 agreement and open market
repurchases. Following this $1 billion share repurchase, Edwards
has $1.4 billion in remaining authorization for additional future
share repurchases.
As previously announced, Edwards is scheduled to speak at the
Wells Fargo Healthcare Conference on Sept. 5 at 10:15 a.m. ET.
During this presentation, Edwards plans to discuss its strategy and
outlook. A live webcast of the presentation will be available on
the Edwards investor relations website at http://ir.edwards.com/,
with an archived version accessible later the same day.
About Edwards
Lifesciences
Edwards Lifesciences is the leading global structural heart
innovation company, driven by a passion to improve patient lives.
Through breakthrough technologies, world-class evidence and
partnerships with clinicians and healthcare stakeholders, our
employees are inspired by our patient-focused culture to deliver
life-changing innovations to those who need them most. Discover
more at www.edwards.com and follow us on LinkedIn, Facebook,
Instagram and YouTube.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
We intend the forward-looking statements contained in this Proxy
Statement to be covered by the safe harbor provisions of such Acts.
These forward-looking statements can sometimes be identified by the
use of forward-looking words, such as “may,” “might,” “believe,”
“will,” “expect,” “project,” “estimate,” “should,” “anticipate,”
“plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,”
“aspire,” “confident” and other forms of these words and include,
but are not limited to, statements made by Mr. Zovighian and
statements regarding our expected financial outcomes, focus on
technology and impact, strategy, and dedication to innovation
following the sale of critical care; anticipated execution of and
benefits resulting from our share repurchases; anticipated
discussion topics and content to be presented at the Wells Fargo
Conference; other objectives and expectations; and other statements
that are not historical facts. Forward-looking statements are based
on estimates and assumptions made by management of the company and
are believed to be reasonable, though they are inherently uncertain
and difficult to predict. Our forward-looking statements speak only
as of the date on which they are made, and we do not undertake any
obligation to update any forward-looking statement to reflect
events or circumstances after the date of the statement. Investors
are cautioned not to unduly rely on such forward-looking
statements.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors as detailed in the company's filings with the Securities
and Exchange Commission. These filings, along with important safety
information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, and the stylized E logo are
trademarks of the Edwards Lifesciences Corporation. All other
trademarks are the property of the respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903401885/en/
Media Contact: Amy Hytowitz, 949-250-4009 Investor
Contact: Mark Wilterding, 949-250-6826
Edwards Lifesciences (NYSE:EW)
過去 株価チャート
から 8 2024 まで 9 2024
Edwards Lifesciences (NYSE:EW)
過去 株価チャート
から 9 2023 まで 9 2024